QualityStocksNewsBreaks – Bio-Path Holdings Inc. (NASDAQ: BPTH) Secures $13M in Public Offering
Bio-Path Holdings (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize(R) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, has closed a public offering of 1,710,600 shares of common stock. Bio-Path Holdings secured approximately $13 million in gross proceeds, with each of the shares sold at the public offering price of $7.60. Bio-Path intends to use the proceeds for working capital and general corporate purposes. ROTH Capital Partners acted as sole placement agent for the offering. For more information about the company, visit www.BioPathHoldings.com About Bio-Path Holdings Inc. Bio-Path Holdings is a biotechnology…
